A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

This study tests zanubrutinib (a targeted oral drug) as maintenance therapy — ongoing treatment to keep cancer from coming back — in patients with mantle cell lymphoma (a type of blood cancer) who have already responded to their first round of treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of mantle cell lymphoma - Your cancer responded well (complete or partial response) to your first treatment, which included at least 4 cycles of chemo-immunotherapy - Previous stem cell transplant is allowed - Your blood counts, liver, kidney, and heart function are within acceptable ranges **You may NOT be eligible if...** - You have a known allergy to zanubrutinib or similar monoclonal antibodies - Your cancer has relapsed or progressed - You have active, uncontrolled infections - You are pregnant or breastfeeding - You have significant heart rhythm problems or uncontrolled bleeding disorders Talk to your doctor to see if this trial is right for you.